However, patients with a higher baseline HBV DNA level (usually > 500 IU/mL or > 2000 IU/mL) were excluded, and whether baseline HBV DNA level affected the clinical prognosis of HCC patients receiving anti-PD-1 based therapy was not assessed in the above clinical trials. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.